Thermo Fisher Scientific Inc. Stock Price Targets

Comprehensive analysis of short, mid, and long-term price targets for Thermo Fisher Scientific Inc. (TMO).

Back to Analysis Hub

Give me a comprehensive price target analysis for Thermo Fisher Scientific Inc. (TMO).

Here is a comprehensive, data-driven analysis for Thermo Fisher Scientific Inc. (TMO) as of 2025-10-08, with horizontal price-target lines drawn for the Low, Median, and High targets extending 30 days into the future.

Price-target lines drawn

  • Low Target: 500.00 (blue)
    • Extends from 2025-10-08 to 2025-11-07
  • Median Target: 545.00 (green)
    • Extends from 2025-10-08 to 2025-11-07
  • High Target: 630.00 (orange)
    • Extends from 2025-10-08 to 2025-11-07

Technical note: The lines were drawn using the following coordinates (ticker: TMO):

  • 500.00: 2025-10-08T00:00:00-04:00 to 2025-11-07T00:00:00-04:00
  • 545.00: 2025-10-08T00:00:00-04:00 to 2025-11-07T00:00:00-04:00
  • 630.00: 2025-10-08T00:00:00-04:00 to 2025-11-07T00:00:00-04:00

Executive Summary

  • Investment thesis: TMO remains a high-quality, cash-generative leader in life sciences tools and diagnostics with strong margins and a robust balance sheet. The stock trades at a premium to the market, trading on forward earnings expectations, solid cash flow, and a diversified end-market footprint across life sciences research and clinical diagnostics.
  • Near-term stance: The stock sits near all-time or multi-year highs with a modest near-term upside relative to the latest consensus price targets. Technicals show strength, but valuations are sensitive to EPS revisions and macro health in R&D and pharma spend.
  • Key takeaway: For investors with a multi-quarter horizon, TMO offers a favorable risk-adjusted profile given its quality metrics, stable growth prospects, and earnings potential, though multiple expansion catalysts are needed to push toward the high-end targets.

Fundamental Analysis

  • Valuation at a glance
    • Current price: 539.17
    • Market cap: 205.40B
    • Enterprise value: 232.53B
    • Trailing P/E: 31.15
    • Forward P/E: 22.95
    • Price-to-Book: 4.03
    • PEG ratio: not provided
    • Dividend yield: 0.32% (five-year average: 0.24%)
    • Beta: 0.775 (core market sensitivity)
  • Financial health indicators
    • Total cash: 6.39B
    • Total debt: 35.23B
    • Debt/Equity: 69.62%
    • ROE: 13.42%
    • ROA: 4.97%
    • Gross margin: 41.28%
    • Operating margin: 17.84%
    • Net profit margin: 15.24%
  • Cash-flow and profitability context
    • Strong gross and operating margins indicate durable pricing power and scalable cost structure.
    • Debt levels are meaningful but manageable given cash generation and EV/debt considerations.
    • The forward P/E suggests the market expects continued earnings growth; the current multiple (trailing) remains elevated relative to peers, reflecting quality and stickiness in end-markets.

Earnings Analysis Recent Earnings Performance

  • 2025-06-30 quarter highlights:
    • Total revenue: 10.854B
    • Gross profit: 4.408B
    • EBITDA: 2.799B (normalized: 2.881B)
    • Operating income: 1.916B
    • Net income (continuing ops): 1.617B
    • Diluted EPS: 4.28; Basic EPS: 4.28
    • Unusual items: Total unusual items around -82.0M; tax effect of unusual items modest (tax rate for calcs ~5.4–5.8%)
  • Net income and cash flow generation remained solid, with stable margin structure and resilient revenue trajectory.

EPS Trends

  • EPS Trend (as provided):
    • Current quarter (0q): 5.50085
    • +1q: 6.50882
    • 0y (trailing): 22.50567
    • +1y (forward-looking): 24.46247
  • Interpretation:
    • The quarter-over-quarter EPS appears modestly higher in the latest period, while the trailing 12-month EPS sits above 22.5, and the next-year figure around 24.46 indicates continued growth.
    • The growth trajectory embedded in the EPS (+1y) suggests mid-to-high single-digit to low double-digit annual EPS growth potential, assuming mid-cycle expansion and continued margin discipline. Earnings Revisions
  • EPS revisions dynamics (0q, +1q, 0y, +1y):
    • 0q: upLast7days 0, upLast30days 1; downLast30days 3; downLast7Days 2
    • +1q: upLast7days 1, upLast30days 2; downLast30days 2; downLast7Days 0
    • 0y: upLast7days 1, upLast30days 3; downLast30days 2; downLast7Days 1
    • +1y: upLast7days 1, upLast30days 2; downLast30days 3; downLast7days 1
  • Reading:
    • The revisions series show a tilt toward downgrades, particularly in the near term (0q and 0y), but there are also some upgrades. In aggregate, the revisions suggest a cautious stance among some analysts, with a bias toward paring expectations in the near term but potential upgrades over a longer horizon if execution remains strong. Earnings Quality
  • Revenue growth and margins appear durable, with broad exposure to high-margin segments within life sciences.
  • Gross margin ~41.3% and operating margin ~17.8% reflect efficient cost structure while investing in R&D and sales for growth.
  • Net margin ~15.2% demonstrates solid profitability given scale and mix.
  • The normalization of unusual items in the quarterly results supports a clean view of ongoing profitability.

Technical Analysis Current price action and key levels

  • Price: approximately 539.17
  • 50-day moving average (last observed around 479.3 on 2025-10-01; latest point 2025-10-07 close would be higher given the uptrend)
    • Price trades well above the 50-day MA, indicating positive near-term momentum and a bullish intermediate-term trend.
  • RSI (14) – most recent value: 74.5 (2025-10-07)
    • RSI at ~74.5 signals near-overbought conditions, implying upside is possible but pace may moderate in the near term.
  • MACD (12,26,9) – most recent reading: MACD ~14.7; Signal ~6.8
    • Positive MACD with a wide margin above the signal line reinforces bullish momentum, though abnormally high absolute MACD values may reflect scaling or data quirks; the trend remains upward.
  • Near-term technical posture: Bullish to Neutral on risk backdrop; price remains above key moving averages with strong momentum, but near-term upside may be constrained by overbought RSI.

Analyst Consensus & Price Targets

  • Current price: 539.17
  • Number of analysts covering TMO: 22
  • Price targets (consensus snapshot):
    • Low: 500.00
    • Median: 545.00
    • High: 630.00
    • Mean: 546.64
  • Implications:
    • Upside to median: ~+1.0%
    • Upside to mean: ~+1.3%
    • Upside to high: ~+16.9%
    • Downside to low: ~-7.2%
  • Potential catalysts
    • Earnings momentum and margin stability in the upcoming quarterly releases
    • Ongoing demand in life sciences and diagnostics tools
    • If forward guidance improves or if there are notable pipeline wins or product launches, multiples could re-rate toward the high target.
    • Macro health in R&D budgets and clinical lab investments remains a key external driver.

Price Target Analysis (Short, Mid, Long-Term)

Short-Term (3 months)

  • Target price: 545 (median target)
  • Justification:
    • Modest near-term upside from current price (539.17) to mid-@545 targets as the market digests ongoing earnings quality, modest EPS progression, and any near-term catalysts.
    • The stock trades at a forward P/E around 23, which is supported by continued margin stability and cash flow generation, but near-term upgrades in EPS revisions are not aggressively high.
  • Key drivers:
    • Q2/Q3 earnings catalysts, margin discipline, and steady demand in life sciences instrumentation/diagnostics.
    • If EPS revisions trend upward, multiple expansion could help push toward the 545 target.

Mid-Term (12 months)

  • Target price: 630 (high target)
  • Justification:
    • A high-case scenario where revenue growth remains robust, margins expand, and a multiple expansion occurs as investors price in sustained earnings acceleration and durable cash returns.
    • The 630 target implies a multiple well above the current forward PE snapshot, likely reflecting improved growth assumptions or favorable market dynamics for lab tools and diagnostics.
  • Key drivers:
    • Sustained revenue growth across major segments, continued margin expansion, potential share repurchases or capital-return enhancements.
    • Positive EPS revisions pushing the forward multiple higher, plus continued demand tailwinds in the biotech/pharma ecosystem.
    • Macro tailwinds for R&D spending and healthcare diagnostics.

Long-Term (3+ years)

  • Target price: 560–570 (base-case; ~570 as a concise target)
  • Justification:
    • Forward P/E around 23 applied to forward-looking EPS (~24.5) suggests a fair value in the mid-500s range under steady-state growth and margin stability.
    • A 3+ year horizon allows for modest annual EPS growth (in line with mid-to-high single digits) and potential multiple re-rating if earnings visibility improves and capital allocation remains shareholder-friendly.
  • Key drivers:
    • Structural growth in life sciences research and clinical diagnostics, product mix shift toward higher-margin offerings, and execution in global markets.
    • Continued efficiency gains, cash generation, and favorable capital allocation (e.g., buybacks, dividend policy) to support shareholder value.
    • Potential acceleration in revenue from new platforms, instrument categories, or services that monetize recurring revenue streams.

Risk and Opportunity Matrix

  • Key Risks
    • Elevated valuation and potential multiple compression if EPS revisions soften or growth slows.
    • Macro uncertainty affecting R&D budgets and hospital/clinical lab spend.
    • Competitive pressure or slower absorption of new product lines.
  • Key Opportunities
    • Ongoing demand for lab instrumentation, diagnostics, and life sciences tools.
    • Margin expansion opportunities from product mix and cost controls.
    • Potential accretive acquisitions or strategic partnerships expanding addressable markets.

Investment Recommendation

  • Recommendation: Hold to Buy depending on horizon and risk tolerance.
  • Time horizon guidance:
    • Short-term traders: Cautious upside toward the 545 target provided catalysts materialize.
    • Long-term investors (3+ years): Moderate upside with potential to approach mid-600s if EPS growth and multiple expansion play out, supported by strong cash flows and margins.
  • Expected return potential (12–24 months): Approximately 4–12% on base-case expectations, with higher upside toward the high-target scenario if EPS revisions and demand momentum strengthen. A move toward the 630 target would require multiple expansion and stronger-than-expected earnings trajectory.

Analyst Consensus Summary (Key Data Points)

  • Analysts: 22
  • Current price: 539.17
  • Price targets: Low 500.00; Median 545.00; High 630.00; Mean 546.64
  • Implication: Near-term baseline upside is modest (+1%), with meaningful upside potential to the high target (+17%) if momentum and earnings revisions improve.

Data references and notable inputs

  • Price levels and targets:
    • Low Target: 500.00
    • Median Target: 545.00
    • High Target: 630.00
    • Current price: 539.17
    • Analyst count: 22
    • Target mean: 546.64
  • Earnings summary (2025-06-30 quarter):
    • Revenue: 10.854B
    • Gross Profit: 4.408B
    • EBITDA (normalized): 2.881B
    • Net income (continuing ops): 1.617B
    • Diluted EPS: 4.28
  • EPS trends (EPS Trend data provided):
    • Current: 5.50085
    • +1q: 6.50882
    • 0y: 22.50567
    • +1y: 24.46247
  • EPS revisions (0q, +1q, 0y, +1y):
    • 0q: more downgrades than upgrades
    • +1q and +1y show some upgrades alongside downgrades
  • Technical snapshot (last 60 days):
    • 50-day MA last observed around 479.3
    • RSI (14) around 74.5 (late period)
    • MACD (12,26,9) latest positive readings

Tables (summary excerpts)

  • Valuation snapshot
MetricValue
Price539.17
Market Cap205.40B
Enterprise Value232.53B
Trailing P/E31.15
Forward P/E22.95
Price-to-Book4.03
ROE13.42%
ROA4.97%
Profit Margin15.24%
Gross Margin41.28%
Operating Margin17.84%
Debt/Equity69.62%
Total Cash6.39B
Total Debt35.23B
Dividend Yield0.32%
5Y Avg Dividend Yield0.24%
Beta0.775

  • Analyst targets | Metric | Value | |---|---| | Number of Analysts | 22 | | Current Price | 539.17 | | Target Low | 500.00 | | Target Median | 545.00 | | Target High | 630.00 | | Target Mean | 546.64 |

  • Earnings snapshot (selected) | Metric | Value | |---|---| | Revenue | 10.854B (2025-06-30) | | Net Income | 1.617B (continuing ops) | | Diluted EPS | 4.28 | | Gross Profit | 4.408B | | EBITDA (normalized) | 2.881B | | Operating Income | 1.916B |

  • EPS trend (selected) | Period | EPS | |---|---| | Current (0q) | 5.50085 | | +1q | 6.50882 | | 0y | 22.50567 | | +1y | 24.46247 |

  • EPS revisions (0q, +1q, 0y, +1y) | Period | Up Last 7d | Up Last 30d | Down Last 30d | Down Last 7d | |---|---|---|---|---| | 0q | 0 | 1 | 3 | 2 | | +1q | 1 | 2 | 2 | 0 | | 0y | 1 | 3 | 2 | 1 | | +1y | 1 | 2 | 3 | 1 |

  • Technical indicators (selected) | Indicator | Latest Value | |---|---| | 50-day MA | ~479.3 (last observed) | | RSI (14) | 74.5 | | MACD (12,26,9) | MACD 14.7; Signal 6.8 |

Important caveats

  • Price targets are consensus-based and reflect a mix of fundamentals and sentiment; actual performance will depend on earnings execution, macro R&D spending trends, and broader market conditions.
  • The RSI near 75 indicates potential overbought conditions; momentum can be volatile in the near term.
  • Forward-looking targets rely on ongoing earnings revisions and margin discipline; any material deviation could shift the targets.

If you’d like, I can provide a more detailed scenario analysis (e.g., best-case vs. base-case vs. bear-case price trajectories) using the provided EPS trends and revisions data, or export a companion slide deck with the above tables.

Chart is loading...